scholarly journals Late Impact of COVID-19 Pneumonia on Testosterone Levels in Recovered, Post-Hospitalized Male Patients

2021 ◽  
Vol 11 (3-4) ◽  
pp. 76-82
Author(s):  
Mohamed M. Aboelnaga ◽  
Ahmed Abdelrazek ◽  
Nahed Abdullah ◽  
Mostafa El Shaer
Keyword(s):  
Testosterone Levels ◽  
Male Patients

scholarly journals Clomiphene fails to revert hypogonadism in most male patients with conventionally treated nonfunctioning pituitary adenomas

2011 ◽  
Vol 55 (4) ◽  
pp. 266-271 ◽  
Author(s):  
Rogerio Silicani Ribeiro ◽  
Julio Abucham
Keyword(s):  
Pituitary Adenomas ◽  
Erectile Function ◽  
Prospective Trial ◽  
Open Label ◽  
Dopaminergic Therapy ◽  
Testosterone Levels ◽  
Nonfunctioning Pituitary Adenomas ◽  
Before And After ◽  
Previously Treated ◽  
Male Patients

OBJETIVE: To evaluate the effect of clomiphene in men with hypogonadism and conventionally treated nonfunctioning pituitary adenomas (NFPA). PATIENTS AND METHODS: Open label, single-arm, prospective trial. Nine hypogonadal men (testosterone < 300 ng/dL and low/normal LH) with previously treated NFPA. Clomiphene (50 mg/day orally) for 12 weeks. Testosterone, estradiol, LH, FSH, prolactin and erectile function were evaluated before and after 10 days, 4, 8 and 12 weeks of clomiphene treatment. RESULTS: After clomiphene treatment, testosterone and erectile function improved in only one patient. In the remaining eight patients, testosterone levels decreased whereas LH, FSH, and estradiol remained unchanged. Insulin sensitivity increased in unresponsive patients. CONCLUSIONS: Compared with hypogonadal men with prolactinomas under dopaminergic therapy, clomiphene treatment failed to restore normal testosterone levels in most patients with conventionally treated NFPA.

scholarly journals Lower testosterone levels predict increasing severity and worse outcomes of hepatitis B virus-related acute-on-chronic liver failure in males

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yandi Huang ◽  
Dong Yan ◽  
Huafen Zhang ◽  
Bin Lou ◽  
Ren Yan ◽  
...  
Keyword(s):  
Liver Disease ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Liver Failure ◽  
Composite Outcome ◽  
Chronic Liver Failure ◽  
Testosterone Levels ◽  
Severity Scores ◽  
B Virus ◽  
Male Patients

Abstract Background Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a serious liver disease with pathogenesis remaining unclear. This study aims to investigate the association between testosterone levels, stage (early, middle, or late, categorized according to clinical manifestation), severity scores, and clinical outcomes of HBV-ACLF. Methods This single-center observational study involved 160 male patients with HBV-ACLF, 151 chronic hepatitis B patients without liver failure (CHB) and 106 healthy controls (HC). Morning blood samples were collected and androgen levels analyzed by chemi-bioluminescent immunoassay. Time to death or liver transplantation within 90 days comprised the primary composite outcome. Results Serum levels of total testosterone (TT), free testosterone index (FTI), dehydroepiandrosterone sulfate and cortisol were significantly lower among HBV-ACLF than CHB and HC, while androstenedione was higher. Low TT, sex hormone binding globulin and FTI were associated with increased stage (of HBV-ACLF, ascites, and hepatic encephalopathy) and severity scores (Model for End-stage Liver Disease and Chinese Group on the Study of Severe Hepatitis B-ACLF scores). Low TT (< 142.39 ng/dL) was a risk factor for both the composite outcome and for death alone within 90 days. Multivariate analysis revealed TT to be an independent predictor for the composite outcome (hazard ratio 2.57, 95% CI 1.09–6.02; P = 0.030). Conclusion Low serum testosterone is common among male patients with HBV-ACLF and predictive of increased severity and worse outcome of the disease and may play an important role in the progression of HBV-ACLF.

scholarly journals Low testosterone is associated with disability in men with multiple sclerosis

2014 ◽  
Vol 20 (12) ◽  
pp. 1584-1592 ◽  
Author(s):  
R Bove ◽  
A Musallam ◽  
BC Healy ◽  
K Raghavan ◽  
BI Glanz ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Hypogonadotropic Hypogonadism ◽  
Total Testosterone ◽  
Cross Sectional ◽  
Testosterone Levels ◽  
Vitamin D Levels ◽  
Relapsing Remitting ◽  
25 Hydroxy Vitamin D ◽  
Male Patients ◽  
Low Testosterone

Background: Gonadal steroids may modulate disease course in multiple sclerosis (MS). Objective: To assess the prevalence and clinical associations of hypogonadism in men with MS. Methods: Male patients, aged 18–65 years, with relapsing–remitting MS (RRMS) or clinically-isolated syndrome (CIS) and their first symptom < 10 years prior were selected from a longitudinal clinical study. We measured their hormones in stored morning blood samples, and collected their Expanded Disability Status Scale (EDSS) scores every 6 months and their Symbol Digit Modalities Test (SDMT) results annually. Results: Our analysis included 96 men with a mean age of 40 years, EDSS of 1.1 and disease duration of 4.6 years. Of these men, 39% were hypogonadal (total testosterone < 288 ng/dL); none showed compensatory elevations in luteinizing hormone. Their low testosterone levels and testosterone:estradiol ratios were negatively correlated with body mass index (BMI) and leptin, and showed no correlation with 25-hydroxy-vitamin D levels. In our primary cross-sectional analyses, there was a negative age-adjusted correlation between total testosterone and EDSS ( p = 0.044). In the age-adjusted longitudinal analyses, higher baseline testosterone levels were associated with less decline in SDMT ( p = 0.012). Conclusions: Men with MS may experience hypogonadotropic hypogonadism. Low testosterone levels may be associated with worse clinical outcomes. A potential neuroprotective role for testosterone warrants further investigation.

scholarly journals Resistance Training and Testosterone Levels in Male Patients with Chronic Kidney Disease Undergoing Dialysis

2014 ◽  
Vol 2014 ◽  
pp. 1-7
Author(s):  
Stig Molsted ◽  
Jesper L. Andersen ◽  
Inge Eidemak ◽  
Adrian P. Harrison ◽  
Niels Jørgensen
Keyword(s):  
Resistance Training ◽  
Muscle Fibre ◽  
Binding Protein ◽  
Muscle Fibres ◽  
Muscle Fibre Size ◽  
Testosterone Levels ◽  
Fibre Size ◽  
Igf Binding ◽  
Male Patients ◽  
Igf Binding Protein

Background.We investigated serum testosterone and insulin-like growth factor 1 (IGF-1) levels’ associations with muscle fibre size and resistance training in male dialysis patients.Methods.Male patients were included in a 16-week control period followed by 16 weeks of resistance training thrice weekly. Blood samples were obtained to analyse testosterone, luteinizing hormone (LH), IGF-1, and IGF-binding protein 3. Muscle fibres’ size was analysed in biopsies fromm. vastus lateralis.Results.The patients’ testosterone levels were within the normal range at baseline (n=20) (19.5 (8.2–52.1) nmol/L versus 17.6 (16.1–18.0), resp.) whereas LH levels were higher (13.0 (5.5–82.8) U/L versus 4.3 (3.3–4.6),P<0.001, resp.). IGF-1 and IGF-binding protein 3 levels were higher in the patients compared with reference values (203 (59–590) ng/mL versus 151 (128–276),P=0.014, and 5045 (3370–9370) ng/mL versus 3244 (3020–3983),P<0.001, resp.). All hormone levels and muscle fibre size (n=12) remained stable throughout the study. Age-adjusted IGF-1 was associated with type 1 and 2 fibre sizes (P<0.05).Conclusion.Patients’ total testosterone values were normal due to markedly increased LH values, which suggest a compensated primary insufficiency of the testosterone producing Leydig cell. Even though testosterone values were normal, resistance training was not associated with muscle hypertrophy. This trial is registered withISRCTN72099857.

scholarly journals Effect of Metformin on Testosterone Levels in Male Patients With Type 2 Diabetes Mellitus Treated With Insulin

2021 ◽  
Vol 12 ◽  
Author(s):  
Tingting Cai ◽  
Yun Hu ◽  
Bo Ding ◽  
Rengna Yan ◽  
Bingli Liu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycated Albumin ◽  
Control Group ◽  
Metformin Therapy ◽  
Testosterone Levels ◽  
Metformin Group ◽  
Male Patients

AimTo explore the chronic effects of metformin on testosterone levels in men with type 2 diabetes mellitus (T2DM).MethodsThis is a secondary analysis of a real-world study evaluating the efficacy and safety of premixed insulin treatment in patients with T2DM via 3-month intermittent flash glucose monitoring. Male patients aged 18-60 who were using metformin during the 3-month study period were included as the metformin group. The control group included males without metformin therapy by propensity score matching analysis with age as a covariate. Testosterone levels were measured at baseline and after 3-month treatment.ResultsAfter 3-month treatment, the control group had higher levels of total testosterone, free and bioavailable testosterone than those at baseline (P&lt;0.05). Compared with the control group, the change of total (-0.82 ± 0.59 vs. 0.99 ± 0.59 nmol/L) and bioavailable (-0.13 ± 0.16 vs. 0.36 ± 0.16 nmol/L) testosterone levels in the metformin group significantly decreased (P=0.036 and 0.029, respectively). In Glycated Albumin (GA) improved subgroup, the TT, FT, and Bio-T levels in the control subgroup were higher than their baseline levels (P &lt; 0.05). Compared with the metformin subgroup, TT level in the control subgroup also increased significantly (P=0.044). In GA unimproved subgroup, the change of TT level in the metformin subgroup was significantly lower than that in the control subgroup (P=0.040).ConclusionIn men with T2DM, 3-month metformin therapy can reduce testosterone levels, and counteract the testosterone elevation that accompanied with the improvement of blood glucose.Clinical Trial Registrationhttps://www.clinicaltrials.gov/ct2/show/NCT04847219?term=04847219&amp;draw=2&amp;rank=1.

scholarly journals Low Pre-Transplant Testosterone Levels in Male Patients Are Associated with Endothelial Vulnerability and Non-Relapse Mortality after Allogeneic Stem Cell Transplantation

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 4587-4587
Author(s):  
Aleksandar Radujkovic ◽  
Dietrich W. Beelen ◽  
Christian Kasperk ◽  
Anthony D. Ho ◽  
Peter Dreger ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Acute Gvhd ◽  
Validation Cohort ◽  
Statin Treatment ◽  
Training Cohort ◽  
Testosterone Levels ◽  
Male Patients

Abstract Introduction: Low testosterone has been demonstrated to be an independent determinant of endothelial (dys)function in men. Graft-versus-host disease (GVHD) is a major contributor to non-relapse mortality (NRM) after allogeneic stem cell transplantation (alloSCT). Vulnerability of the recipients' endothelial cell system is a novel concept to explain why a proportion of patients with acute GVHD fail to respond to escalating immunosuppressive therapy and ultimately succumb to GVHD and related complications. This retrospective study investigated the prognostic impact of pre-transplant testosterone levels on NRM after alloSCT in male patients. Patients and methods: Between 2002 and 2014, a total of 277 male patients undergoing alloSCT at Heidelberg University (median age 55 years) provided informed consent to participate in this observational study (training cohort). 71 patients (26%) received transplants from related donors (RD). Diagnoses were acute myeloid leukemia (AML) in 108 patients (48%), myelodysplastic syndrome (MDS) in 66 patients (29%), lymphoid malignancies (lymphoma, chronic and acute lymphoid leukemia) in 75 patients (33%), and multiple myeloma in 28 patients (12%). A total of 176 patients (78%) received statin treatment post alloSCT as per institutional standard policy. For validation, an independent patient cohort of 205 men allografted for AML and MDS (median age 57 years, 18% RD, no statin treatment) at Essen University was analysed. Pre-transplant serum samples for testosterone measurements were collected between 0 and 2 months before alloSCT and cryopreserved at -80°C. Testosterone concentrations were measured by radioimmunoassay. Pre-transplant levels of suppressor of tumorigenicity-2 (ST2) were determined by ELISA. Overall survival (OS), incidence of relapse and NRM and were calculated from date of alloSCT to the appropriate endpoint using Cox regression analysis with cause specific hazard models for NRM and relapse. As confounding prognostic factors we included testosterone levels, age, donor type, graft type, donor sex, conditioning intensity, and disease type and stage prior to alloSCT. Results: Median pre-transplant testosterone level in the training and validation cohort was 13.6 nmol/L (range 0.3-41.7 nmol/L) and 16.0 nmol/L (0.8-38.1 nmol/L), respectively. In the training cohort, lower pre-transplant testosterone as continuous variable was associated with shorter OS (p=0.009). Lower testosterone levels showed a trend towards higher NRM (p=0.09) and a significant association with NRM after onset of acute GVHD (p=0.02). Multivariate analysis confirmed that lower pre-transplant testosterone levels were a significant predictor of an increased NRM risk after GVHD onset (p=0.03). In the subgroup of patients not receiving statins post-transplant, lower testosterone levels were associated with increased incidence of transplant-associated microangiopathy (p=0.01). In addition, lower pre-transplant testosterone levels correlated with higher pre-transplant ST2 levels indicating endothelial vulnerability. In the validation cohort, similar results with regard to OS (p=0.02), NRM (p=0.04), NRM after acute GVHD onset (p=0.03) in univariate analysis, and to NRM after GVHD onset (p=0.02) in multivariable analysis could be observed. The association of pre-transplant testosterone levels (in quartiles) and incidence of NRM after GVHD onset in the training and validation cohort is depicted in Figure 1A and 1B, respectively. Conclusion: Our study suggests that low pre-transplant testosterone is associated with serological and clinical evidence for endothelial damage and is an independent risk factor for a fatal outcome of GVHD. Prospective studies in the alloSCT setting investigating testosterone and testosterone supplementation in deficient patients are highly warranted. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

THE EFFECTS OF CLOMIPHENE ON ENDOCRINE FUNCTION IN MALE PATIENTS WITH ADRENOCORTICAL INSUFFICIENCY AND FOLLOWING CASTRATION

1968 ◽  
Vol 58 (1) ◽  
pp. 38-48 ◽  
Author(s):  
R. A. Harkness ◽  
E. T. Bell ◽  
J. A. Loraine ◽  
A. A. A. Ismail ◽  
W. I. Morse
Keyword(s):  
Follicle Stimulating Hormone ◽  
Endocrine Function ◽  
Adrenocortical Insufficiency ◽  
Marked Rise ◽  
Testosterone Levels ◽  
Main Effect ◽  
Male Patients ◽  
Stimulating Hormone

ABSTRACT The effect of clomiphene administration on steroid and gonadotrophin output has been studied in three male patients with adrenocortical insufficiency and in three castrate men. In the patients with adrenocortical insufficiency the main effect of clomiphene was to produce a marked increase in the output of urinary testosterone and of its metabolites, androsterone and aetiocholanolone. It is concluded that this effect results from testicular stimulation. In the castrate males clomiphene caused a less marked rise in the excretion of dehydroepiandrosterone (DHA), androsterone and aetiocholanolone, presumably indicating adrenocortical stimulation. Testosterone levels may have fallen slightly during the administration of the compound. Little or no effect on the output of »total gonadotrophic activity« or of follicle-stimulating hormone (FSH) was produced by clomiphene.

Sign in / Sign up

Export Citation Format

Share Document